Oncolytics Biotech, Inc.

Twitter LinkedIn
  • Home
  • About
    • Our Company
    • Management Team
    • Board of Directors
  • Technology
    • What is Pelareorep?
    • What Does Pelareorep Do?
    • Delivery
    • Intellectual Property
    • Posters & Publications
    • Manufacturing
  • Clinical Trials
    • Clinical Development Plan
    • Collaborators
    • Pipeline
  • Media
    • Press Releases
    • Insights
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Filings & Financials
    • Corporate Governance
    • FAQs
    • Email Alerts
    • IR Contacts
  • Contact
  • Careers

News

Media

Media

  • Press Releases
  • Insights
Apr 26, 2017

Oncolytics Biotech® Inc. to Present at the Sixth Annual Bloom Burton & Co. Healthcare Investor Conference

Apr 12, 2017

Oncolytics Biotech® Inc. Announces Registration Pathway and Clinical Development Plan

Apr 5, 2017

Oncolytics Biotech® Inc.'s REOLYSIN® More than Doubles Overall Survival in Patients with Mutated p53 Metastatic Breast Cancer

Mar 31, 2017

Oncolytics Biotech® Inc.'s REOLYSIN® Provides Statistically Significant Improvement in Overall Survival in Canadian Cancer Trials Group Sponsored Randomized Phase 2 Study in Metastatic Breast Cancer

Mar 16, 2017

Oncolytics Biotech® Inc. Enters into First-in-Class Collaboration with Myeloma UK and Celgene Using REOLYSIN® in Combination with Imnovid® or Revlimid® in Patients with Myeloma

Mar 10, 2017

Oncolytics Biotech® Inc. Announces 2016 Year-End Results

Mar 2, 2017

Oncolytics Biotech® Inc. Announces Canadian Cancer Trials Group to Present Final Randomized Data from Phase 2 Metastatic Breast Cancer Study at AACR 2017 Annual Meeting

Jan 19, 2017

Oncolytics Biotech® Inc. Appoints Dr. Matt Coffey to the Role of President and CEO

Dec 6, 2016

Oncolytics Biotech® Inc. Announces Change to Board of Directors

Dec 6, 2016

Oncolytics Biotech® Inc. Collaborators Present Initial Results from REO 019 Study in Multiple Myeloma Combining REOLYSIN®, Bortezomib and Dexamethasone at the ASH Annual Meeting

    • 1...
    • 12
    • 13
    • 14
    • 15
    • 16
    • 17
    • 18
    • 19
    • 20
    • 21
    • ...53
    © 2021 Oncolytics Biotech, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap